PURPOSE: To investigate the plasma levels of amyloid beta (Aβ) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity. METHODS: Plasma samples were obtained from AMD subjects at various stages of disease-early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)-and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (Aβ isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables. RESULTS: Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of Αβ isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma Aβ 1-42 levels, and its ratio with Aβ 1-40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for Αβ isotypes, the ROC curve showed a moderate prediction (AUC = - ~ 0.78) of AMD vs control using the Aβ 1-42 isotype. CONCLUSION: Plasma Aβ 1-42 may have utility as a systemic biomarker for AMD.
PURPOSE: To investigate the plasma levels of amyloid beta (Aβ) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity. METHODS: Plasma samples were obtained from AMD subjects at various stages of disease-early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)-and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (Aβ isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables. RESULTS: Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of Αβ isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma Aβ 1-42 levels, and its ratio with Aβ 1-40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for Αβ isotypes, the ROC curve showed a moderate prediction (AUC = - ~ 0.78) of AMD vs control using the Aβ 1-42 isotype. CONCLUSION: Plasma Aβ 1-42 may have utility as a systemic biomarker for AMD.
Authors: Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Jin-Dong Ding; John Lin; Brian E Mace; Rolf Herrmann; Patrick Sullivan; Catherine Bowes Rickman Journal: Vision Res Date: 2007-09-20 Impact factor: 1.886
Authors: Ronald Klein; Barbara E K Klein; Michael D Knudtson; Tien Yin Wong; Anoop Shankar; Michael Y Tsai Journal: Am J Ophthalmol Date: 2005-07 Impact factor: 5.258
Authors: Luba Robman; Paul N Baird; Peter N Dimitrov; Andrea J Richardson; Robyn H Guymer Journal: Ophthalmology Date: 2010-06-03 Impact factor: 12.079
Authors: N Ertekin-Taner; L H Younkin; D M Yager; F Parfitt; M C Baker; S Asthana; M L Hutton; S G Younkin; N R Graff-Radford Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Lincoln V Johnson; William P Leitner; Alexander J Rivest; Michelle K Staples; Monte J Radeke; Don H Anderson Journal: Proc Natl Acad Sci U S A Date: 2002-08-20 Impact factor: 11.205
Authors: Chengxuan Qiu; Jie Ding; Sigurdur Sigurdsson; Diana E Fisher; Qian Zhang; Gudny Eiriksdottir; Ronald Klein; Mark A van Buchem; Vilmundur Gudnason; Mary Frances Cotch; Lenore J Launer Journal: Neurology Date: 2017-12-13 Impact factor: 9.910
Authors: Valentina Cipriani; Laura Lorés-Motta; Fan He; Dina Fathalla; Viranga Tilakaratna; Selina McHarg; Nadhim Bayatti; İlhan E Acar; Carel B Hoyng; Sascha Fauser; Anthony T Moore; John R W Yates; Eiko K de Jong; B Paul Morgan; Anneke I den Hollander; Paul N Bishop; Simon J Clark Journal: Nat Commun Date: 2020-02-07 Impact factor: 14.919
Authors: Laura Lorés-Motta; Anna E van Beek; Esther Willems; Judith Zandstra; Gerard van Mierlo; Alfred Einhaus; Jean-Luc Mary; Corinne Stucki; Bjorn Bakker; Carel B Hoyng; Sascha Fauser; Simon J Clark; Marien I de Jonge; Everson Nogoceke; Elod Koertvely; Ilse Jongerius; Taco W Kuijpers; Anneke I den Hollander Journal: Am J Hum Genet Date: 2021-07-13 Impact factor: 11.025